Author:
Carpio Arturo,Campoverde Alfredo,Romo Matthew L.,García Lorena,Piedra Luis M.,Pacurucu Mónica,López Nelson,Aguilar Jenner,López Sebastian,Vintimilla Luis C.,Toral Ana M.,Peña-Tapia Pablo
Abstract
Objective:To prospectively evaluate the validity of a PCR assay in CSF for the diagnosis of neurocysticercosis (NC).Methods:We conducted a multicenter, prospective case-control study, recruiting participants from 5 hospitals in Cuenca, Ecuador, from January 2015 to February 2016. Cases fulfilled validated diagnostic criteria for NC. For each case, a neurosurgical patient who did not fulfill the diagnostic criteria for NC was selected as a control. CT and MRI, as well as a CSF sample, were collected from both cases and controls. The diagnostic criteria to identify cases were used as a reference standard.Results:Overall, 36 case and 36 control participants were enrolled. PCR had a sensitivity of 72.2% (95% confidence interval [CI] 54.8%–85.8%) and a specificity of 100.0% (95% CI 90.3%–100.0%). For parenchymal NC, PCR had a sensitivity of 42.9% (95% CI 17.7%–71.1%), and for extraparenchymal NC, PCR had a sensitivity of 90.9% (95% CI 70.8%–98.9%).Conclusions:This study demonstrated the usefulness of this PCR assay in CSF for the diagnosis of NC. PCR may be particularly helpful for diagnosing extraparenchymal NC when neuroimaging techniques have failed.Classification of evidence:This study provides Class III evidence that CSF PCR can accurately identify patients with extraparenchymal NC.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Clinical Neurology,Neurology
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献